Liberty signs amended licensing agreement with Aphria to include Solei in its growing portfolio of products

TORONTO, May 11, 2018 /PRNewswire/ – Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) (“Liberty” or the “Company“) today announced it has signed an amended licensing agreement with Aphria Inc. (“Aphria“) to add Solei Sungrown Cannabis (“Solei“), to the Company’s growing portfolio of brands. Under the terms of the agreement, Liberty will be able to produce and sell Solei in Florida and Massachusetts, subject to receipt of all required approvals from the Florida Department of Health, Office of Medical Marijuana Use, and from the Commonwealth of Massachusetts, Medical Use of Marijuana Program or the Massachusetts Cannabis Control Commission, if any.

“We are incredibly excited to introduce Solei to the U.S. and to make this brand available to our patients throughout Florida, and soon Massachusetts,” said George Scorsis, Director and CEO of Liberty. “Solei is the perfect complement to Liberty’s patient-centric approach to medical cannabis. Solei hopes to make medical cannabis understandable to all of our patients in need in an easy-to-understand format.”

Solei will be available in a wide variety of product consumption alternatives, with easy-to-use instructions designed to simplify cannabis use.

“Aphria is delighted to extend our strategic relationship with Liberty, as they continue to demonstrate leadership in Florida and soon other legal markets in the U.S.,” said Vic Neufeld, CEO of Aphria. “Medical cannabis patients in Florida and elsewhere will benefit from Solei’s uncomplicated and simplified approach to consuming cannabis, which really sets the brand apart in the marketplace.”

Liberty’s Cannabis Education Centers will offer Solei alongside the Company’s currently lineup of brands to be offered to patients in Florida, including Aphria, Mary’s Medicinals, incredibles, incredible Extracts, and incredible Wellness. Solei products are expected to be available

Read More Here...